The European Respiratory Society (ERS) Clinical Practice Guidelines update for Pulmonary Arterial Hypertension (PAH) were presented today at the ERS Congress!
The Alliance for Pulmonary Hypertension Vice President Louise Bouman – van der Waal was at the congress and attended this important session.
Here is the link to the article: https://lnkd.in/evX7wHhe
Pisana Ferrari, President of the Alliance for Pulmonary Hypertension, represented the patient community in the task force, bringing the patient perspective and unique patients insights.
The Task Force recommends add-on treatment with sotatercept in PAH patients who already receive PAH drugs and are at intermediate-low, intermediate-high or high risk of death during follow-up; this recommendation is based on a high certainty of evidence available from randomised controlled trials (RCTs). In PAH patients at low risk of death, the Task Force does not provide a recommendation due to the low certainty of evidence and the limited number of such patients included in RCTs.
Patients are placed at the centre of the new guideline’s approach. Outcomes are explicitly framed around how patients feel alongside function and survival. Shared decision-making is a core principle, with the right heart catheterisation recommendation deliberately left to patient and doctor together, weighing individual preferences and treatment burden. Treatment burden is also carefully weighed throughout.
The new guidelines mark a meaningful step forward for the PAH patient community.
Big thank you to the Chairs Marion Delcroix and Gabor Kovacs for their excellent leadership!